Genetic Testing for Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome
This 40-year-old patient with multiple cutaneous leiomyomas (piloleiomyomas) requires immediate genetic testing for fumarate hydratase (FH) gene mutations to diagnose HLRCC syndrome, followed by annual renal MRI surveillance if positive, as this condition carries a 21% lifetime risk of aggressive renal cell carcinoma by age 70. 1
Critical Evaluation Algorithm
Step 1: Assess for HLRCC Syndrome Risk
The presence of multiple piloleiomyomas is the key clinical trigger. In patients with multiple cutaneous leiomyomas, HLRCC is confirmed in 73% of cases 2. The clinical presentation described—multiple firm papules/nodules on trunk and extensor surfaces with episodic pain triggered by cold or pressure—is pathognomonic for piloleiomyomas associated with HLRCC 3, 4.
Key distinguishing features:
- Multiple lesions = high HLRCC risk (73% positive rate)
- Solitary lesions = typically sporadic, not associated with HLRCC 2, 5
- Patients with HLRCC present younger (mean age 35 years vs. 56 years for sporadic cases) 2
- Involvement of both trunk AND upper extremities increases mutation probability 2
Step 2: Order Genetic Testing
Obtain whole exome sequencing or targeted FH gene sequencing from peripheral blood to identify heterozygous germline pathogenic variants in the fumarate hydratase gene 3. This is diagnostic for HLRCC syndrome.
Step 3: Initiate Renal Cancer Surveillance if Positive
The mortality risk from HLRCC comes entirely from renal cell carcinoma, not from the cutaneous lesions. Annual renal MRI surveillance is mandatory starting immediately upon diagnosis 1.
Specific surveillance protocol:
- MRI without contrast with diffusion-weighted imaging annually 1
- If a renal lesion is detected, obtain MRI with contrast for characterization 1
- Age-related RCC penetrance: 2% by age 40, increasing to 21% by age 70 1
The 2025 Clinical Cancer Research guidelines emphasize that while surveillance typically begins at age 10 in known carriers, this 40-year-old patient is already in the high-risk window and requires immediate initiation 1.
Management of Cutaneous Lesions
Treat only symptomatic lesions—surveillance of the skin lesions themselves is not recommended 1. The cutaneous leiomyomas are benign, and malignant transformation is exceedingly rare 1.
Treatment options for painful lesions:
- Surgical excision (curative for individual lesions) 5
- Medical therapy for pain control (calcium channel blockers, alpha-blockers, nitroglycerin, gabapentin)
- Destructive therapies (cryotherapy, laser) 5
Critical caveat: Educate the patient to report rapid growth or concerning changes in any cutaneous lesion, as malignant transformation, though infrequent, does occur in adults 1.
Family Screening
Screen first-degree relatives for cutaneous leiomyomas and consider genetic testing, as HLRCC follows autosomal dominant inheritance 1. Family members who are heterozygous carriers require the same renal surveillance protocol.
Common Pitfalls to Avoid
Do not dismiss multiple painful skin nodules as benign without genetic evaluation—the renal cancer risk is life-threatening and requires lifelong surveillance 1
Do not use ultrasound for renal surveillance—MRI is superior for detecting HLRCC-associated RCC 1
Do not confuse piloleiomyomas with other painful skin tumors (angioleiomyomas, glomus tumors, neuromas)—histology showing smooth muscle bundles from arrector pili distinguishes piloleiomyomas 5
Do not assume solitary lesions indicate HLRCC—only multiple piloleiomyomas warrant genetic testing 2, 5